Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced on July 8, 2005, the establishment of a pharmaceuticals marketing subsidiary, Eisai AB, in Sweden to expand business in the four Nordic countries (Sweden, Denmark, Finland and Norway). Eisai AB is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).
In the Nordic market, Eisai AB plans to sell and promote pharmaceuticals mainly in the neurology area including the anti-epileptic drugs
Zonegran
and
Inovelon, for which a marketing application has been submitted to the European Medicines Evaluation Agency. The newly established subsidiary company will also promote active business development, and aims at establishing an efficient and profitable business framework.
In Europe, Eisai already has marketing subsidiaries in the U.K., France, Germany, Spain, Italy and Switzerland. The U.K. and German subsidiaries have branch offices in Ireland and Austria, respectively. The entry to the Nordic market will allow the Company to cover the major European markets and further expand its sales network over the area.
Eisai AB will establish a business structure in the four Nordic countries and will provide a stable supply of high quality products and appropriate product information for safe and proper usage to meet the medical needs of patients in these countries.
[Company Outline]
| Company Name : | Eisai AB |
| Capital : | SEK 10 million (approx. 150 million yen) |
| Location : | Stockholm, Sweden |
| Operations : | Promotion/sale of pharmaceuticals |
